A comparison of deep brain stimulation and continuous intrajejunal levodopa infusion in advanced Parkinson’s disease: The INVEST study
Objective: To compare costs and effectiveness of the therapies DBS and CLI in advanced PD. Background: The therapies deep brain stimulation (DBS) and continuous intrajejunale…Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy
Objective: Here we report the case of a 49-year-old man with a 19 years history of PD presenting DDS while he was on LCIG therapy.…Contributions of sensorial feedback to gait in Parkinson’s disease
Objective: To evaluate the integration of optic flow and proprioception when people with Parkinson's disease (PD), under and without dopaminergic medication effects, and matched-control group…Implications of direct and indirect costs in health-related quality of life in Parkinson’s disease: A cross-sectional study in Mexico
Objective: To evaluate the association of direct and indirect costs of Parkinson's disease (PD) and health-related quality of life (HRQoL) in a Mexican population. Background:…Impulsive-compulsive behaviors in patients with Parkinson’s disease and demographically-comparable group of healthy controls
Objective: To assess patients with Parkinson's disease (PwPD) impulsive-compulsive behaviors (ICBs) prevalence compared to healthy controls (HCs) group, to analyze PD clinical features, ICBs risk…Dynamic prediction for multiple repeated measures and event time data: An application to Parkinson’s disease
Objective: To develop methods for model-based personalized dynamic prediction of future outcome measure trajectories and risks of target events for the Parkinson's disease patients. Background:…Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial
Objective: To compare hospitalisation rates of Parkinson's disease (PD) patients randomised between three different classes of oral medications used for early PD treatment. Background: PD…Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…Developing a new home monitoring device for dyskinesia in Parkinson’s disease
Objective: To evaluate how accurately a new device can discriminate different clinical severities of dyskinesia from non-dyskinetic movements in patients with Parkinson's disease (PD). Background:…Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios
Objective: To determine predictors of response and conversion ratios for a novel extended release levodopa preparation. Background: A new extended release levodopa preparation, Rytary®, has…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.